

FTGF Putnam Global Healthcare Fund

IE000LOQHL30
Sector | Factsheet as of 31 March 2026

This is a marketing communication. Please refer to the offering documents before making any final investment decisions.

Risk Considerations


INVESTMENT INVOLVES RISKS. The value of the Fund can be volatile and investors may not get back the amount originally invested. Past performance is not indicative of future results.

- The Fund is a sub-fund of Franklin Templeton Global Funds plc, an open-ended umbrella investment company constituted in Ireland. The Fund seeks to generate long-term capital appreciation by investing at least 90% of its net asset value in equity and equity-related securities of healthcare-related companies.
- Investors will be exposed to investment risk, concentration risk, risk of investing in healthcare sector, equity and equity-related securities risk, emerging markets risk, custody and settlement risks, currency risk and derivatives risks.
- Investors should not invest based on this marketing material alone. Offering documents should be read for further details, including the risk factors. Before you decide to invest, you should make sure the intermediary has explained to you that the Fund is suitable to you.

Past performance does not predict future returns.

Performance From Inception in Share Class Currency (%)

■ FTGF Putnam Global Healthcare Fund - A USD ACC



Total Returns (%)

| | Cumulative | | | | | | Annualised | | | Inception Date | |
|-----------------|------------|-------|-------|------|------|------|------------|------|------|----------------|-----------|
| | 1-Mo | 3-Mo | YTD | 1-Yr | 3-Yr | 5-Yr | Inception | 3-Yr | 5-Yr | | |
| A USD ACC | -7.07 | -3.30 | -3.30 | – | – | – | 13.88 | – | – | 13.88 | 30/5/2025 |
| Benchmark (USD) | -8.28 | -4.60 | -4.60 | – | – | – | 10.25 | – | – | 10.25 | – |

Calendar Year Returns (%)

| | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|-----------------|-------|------|------|------|------|------|------|------|------|------|
| A USD ACC | 17.77 | – | – | – | – | – | – | – | – | – |
| Benchmark (USD) | 15.57 | – | – | – | – | – | – | – | – | – |

Investment Objective

To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of healthcare-related companies (companies that operate in, or are related to, the major subsectors of the healthcare sector, including pharmaceuticals, biotechnology, healthcare technology, life sciences tools and services, healthcare equipment and supplies, and healthcare providers and services).

Fund Overview

| | |
|----------------------------|-------------------------------------|
| Umbrella | Franklin Templeton Global Funds plc |
| Fund Base Currency | USD |
| Fund Inception Date | 30/05/2025 |
| Share Class Inception Date | 30/05/2025 |
| Minimum Investment (USD) | 1000 |
| ISIN | IE000LOQHL30 |
| Bloomberg | FPGHAUS ID |
| Morningstar Peer Group | Sector Equity Healthcare |
| EU SFDR Category | Article 8 |

Benchmark(s) and Type

| | |
|---------------------------------|------------|
| MSCI World Health Care Index-NR | Comparator |
|---------------------------------|------------|

Fund Characteristics

| | Fund |
|--------------------------------------|----------------|
| NAV-A USD ACC | \$113.88 |
| Total Net Assets (USD) | \$3.72 Million |
| Number of Issuers | 38 |
| Average Market Cap (Millions USD) | \$282,725 |
| Price to Book | 5.56x |
| Price to Earnings (12-Month Forward) | 18.84x |

Top Equity Issuers (% of Total)

| | Fund |
|--------------------------|------|
| Johnson & Johnson | 9.18 |
| Eli Lilly | 8.65 |
| AbbVie | 6.26 |
| Novartis | 5.23 |
| UnitedHealth | 5.14 |
| Merck | 4.95 |
| AstraZeneca | 4.92 |
| Thermo Fisher Scientific | 4.50 |
| Intuitive Surgical | 4.05 |
| Sanofi | 3.58 |

Sector Allocation (% of Total)

| | Fund | Benchmark |
|--------------------------------|-------|-----------|
| Pharmaceuticals | 45.43 | 47.79 |
| Biotechnology | 20.19 | 16.38 |
| Health Care Equipment | 10.33 | 14.15 |
| Managed Health Care | 5.14 | 4.52 |
| Life Sciences Tools & Services | 5.01 | 6.92 |
| Health Care Distributors | 4.95 | 2.92 |
| Health Care Services | 2.27 | 3.18 |
| Health Care Supplies | 1.40 | 2.54 |
| Other | 1.54 | 1.59 |
| Cash & Other Net Assets | 3.74 | 0.00 |

Geographic Allocation (% of Total)

| | Fund | Benchmark |
|-------------------------|-------|-----------|
| United States | 71.62 | 70.88 |
| Switzerland | 7.97 | 9.71 |
| United Kingdom | 5.92 | 6.10 |
| France | 3.58 | 2.48 |
| Japan | 2.29 | 3.97 |
| Denmark | 2.06 | 1.85 |
| Belgium | 1.19 | 0.55 |
| Netherlands | 1.09 | 0.95 |
| Others | 0.53 | 3.51 |
| Cash & Other Net Assets | 3.74 | 0.00 |

Market Cap Breakdown (% of Total) (USD)

| | Fund |
|-----------------------|-------|
| Less than \$1.4B | 0.25 |
| \$5.2B - \$30.6B | 4.61 |
| \$30.6B - \$130.7B | 30.87 |
| Over \$130.7B | 60.52 |
| Cash and other assets | 3.74 |

Share Class Details

| | ISIN | Dividends | |
|-----------|--------------|---------------------|---------------|
| | | Max. Initial Charge | Annual Charge |
| A USD ACC | IE000LQHL30 | 5.00% | 1.40% |
| A HKD ACC | IE000FBJ54P3 | 5.00% | 1.40% |

Annual Charge quoted indicates the maximum annual Management Fee (expressed as a percentage of the Fund's NAV attributable to the respective share class). Actual dividend amount may be different from the aforementioned figures due to rounding. Only dividend records within the past 12 months are displayed. Dividend amounts are quoted in the currency of the respective share class. Annual Charge includes Management Fee and Maintenance Charge.

Portfolio Management

| | Years with Firm | Years of Experience |
|-------------------|-----------------|---------------------|
| Mike Maguire, CFA | 17 | 24 |

Glossary

Comparator: Benchmark is used for comparing Fund performance, but is not a constraint to Fund Investment. **Weighted Average Market Capitalization:** A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-month Forward):** A measure of the price to earnings ratio for a stock using the forecasted earnings for the next 12 months. For a portfolio, the value represents a weighted average of the stocks it holds. **Charges:** For a comprehensive list of the types of costs deducted from fund assets, see the offering documents.

Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

Important Information

This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.

This classification does not represent the fund is authorised as a Green or environmental, social and governance (ESG) fund in Hong Kong. Please visit the full list of SFC-authorized ESG funds at: <https://www.sfc.hk/en/regulatory-functions/products/list-of-esg-funds>.

This material is intended to be of general interest only and should not be construed as investment advice. It does not constitute legal or tax advice and it is not an offer for shares or an invitation to apply for shares of the Irish-domiciled Franklin Templeton Global Funds plc (the "Fund" or "FTGF"). For the avoidance of doubt, if you decide to invest, you will be buying units in the Fund and will not be investing directly in the underlying assets of the Fund.

Franklin Templeton ("FT") provides no guarantee or assurance that the Fund's investment objective will be attained. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. **Past performance is not an indicator or a guarantee of future performance.** Currency fluctuations may cause the value of a Fund's investments to diminish or increase.

FT shall not be liable to any user of this document or to any other person or entity for the inaccuracy of information or any errors or omissions in its contents, regardless of the cause of such inaccuracy, error or omission. Any opinions expressed are the author's at publication date and they are subject to change without prior notice. Any research and analysis contained in this material has been procured by FT for its own purposes and is provided to you only incidentally. Data from third party sources may have been used in the preparation of this document and FT has not independently verified, validated or audited such data.

No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for public distribution in all jurisdictions and prospective investors, who are not financial professionals, should consult their financial advisor before deciding to invest. The Fund may use financial derivatives or other instruments which may entail specific risks more fully described in the Fund's Documents.

Subscriptions to shares of the Fund should only be made on the basis of the Fund's current Prospectus, and, where available, the relevant offering documents.

In addition, a Summary of Investor Rights is available from <https://www.franklintempleton.com.hk/en-hk/about-us/summary-of-investor-rights>. The summary is available in English and Chinese.

The sub-funds of FTGF are notified for marketing in multiple EU Member States under the UCITS Directive. FTGF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

Performance information is based on the stated share class only, in Fund Currency, NAV to NAV, taking into account of dividend reinvestments and capital gain or loss.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Hedged share classes will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

© **Morningstar, Inc.** All rights reserved. The information contained here in (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Benchmark: Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com. Source: MSCI makes no warranties and shall have no liability with respect to any MSCI data reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Net Returns (NR) include income net of tax withholding when dividends are paid.

Hong Kong, Taiwan and Macau: Issued by Franklin Templeton Investments (Asia) Limited, 62/F, Two IFC, 8 Finance Street, Central, Hong Kong.

For further information on paying agents and representative agents of FTGF, please refer to the Fund's Prospectus.

This document has not been reviewed by the Securities and Futures Commission in Hong Kong or Monetary Authority of Macao in Macau.

This document is intended to be of general interest only. Distribution of this document may be restricted in certain jurisdictions: the document may not be used other than by the distributors in Macau and master agent in Taiwan. For Macau, those funds are not domiciled in the Macau Special Administrative Region ("SAR") and that the regulatory standards may differ from those applicable in the Macau SAR. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund or security. **Investment involves risks.** Past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD ("other foreign currency"). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase or sell securities, and the information provided regarding such individual securities is not a sufficient basis upon which to make an investment decision. Fund allocations, holdings and characteristics are subject to change at any time. Franklin Templeton may have an interest in the acquisition or disposal of the securities mentioned herein.

Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Unless stated otherwise, all information is as of the date of this document. Source: Franklin Templeton.

© 2026 Franklin Templeton. All rights reserved.

Offering Documents



Shareholder Letter

